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Aim: The aim of this paper is to summarize the treatment outputs of secondary angiosar-
coma  after breast conservation therapy at St. Eizabeth Cancer Centre, Slovakia.
Background: Angiosarcoma of the breast is a rare but very aggressive malignant tumor of
the  vascular endothelium, characterized by rapidly proliferating and extensively inﬁltrating
growth. Breast angiosarcoma may occur de novo, or as a complication of radiation therapy,
or  chronic lymphedema secondary to axillary lymph node dissection for mammary carci-
noma. Radiotherapy in the treatment of breast cancer is associated with an increased risk
of  subsequent sarcoma.
Materials and methods: Retrospective study of medical records from the cancer databases was
done in order to analyze the secondary breast angiosarcoma. This disease is an iatrogenic
condition that warrants close follow-up and judicial use of radiotherapy in breast conserv-
ing  therapy. Therefore, it is more prevalent in cases treated with radiotherapy, occurring
especially in or adjacent to the radiation ﬁeld. Clinical histories and follow-up data of iden-
tiﬁed patients after breast conservation therapy of invasive breast cancer were reviewed.
In  addition, a comprehensive literature review on diagnosis and treatment procedures was
done in order to summarize state-of-the-art clinical approach.
Results and discussions: Three cases of secondary angiosarcoma after breast conservation
therapy (BCT) were identiﬁed among 4600 patients treated at St. Elizabeth Cancer Institute
during previous 16 years (1995–2011). Secondary breast angiosarcoma was diagnosed in a
median period of 11 years following primary radiotherapy, median age at the time of diag-urgical treatment consisted of radical mastectomy. The ﬁrst patient,nosis was 75 years. Sa  56-year-old woman received neoadjuvant chemotherapy (docetaxel + gemcitabin), second
one  (75 year) was treated by radiotherapy (TD 26 Gy, 2 Gy per fraction), since chemotherapy
was not indicated. The last patient (80 year) got adjuvant chemotherapy (paclitaxel). Aver-
age  follow up of the patients was 31 months. As of 31 July 2012, our patients were doing well
without evidence of recurrent disease after treatment.
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Conclusions: Angiosarcoma remains a difﬁcult management problem with poor loco-regional
and  distal control. In our study, an overall incidence rate of secondary breast angiosarcoma
is  0.065%. Although the prognosis for this disease is poor (typical survival period is 14.5–34
months with a 5-year survival rate of approximately 15%), all the three patients treated at
our  institute are alive and disease-free at the end of reported period. Finally, it is assumed
that the use of breast conserving therapy will increase the incidence of post-irradiation
angiosarcoma but the small difference in risk of subsequent sarcoma of the breast cancer
patients receiving radiotherapy does not suppress its beneﬁt.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All1.  Background
Angiosarcoma (AS) is a very aggressive malignant tumor of
the vascular endothelium, characterized by rapidly prolifer-
ating and extensively inﬁltrating growth and it may occur in
any organ of the body. This malignancy can originate in the
liver, breast, spleen, bone or heart’; however, it most frequently
arises in the skin and soft tissue. Approximately 1–2% of all
soft-tissue sarcomas are angiosarcomas, approximately 8% of
which arise in the breast.1,2 In Europe, soft tissue sarcomas
have estimated incidence averaging 5/100,000/year.3 Breast AS
may occur de novo or as a complication of radiotherapy (RT)
or chronic lymphedema after radical mastectomy for mam-
mary carcinoma (Stewart–Treves Syndrome).4–6 The frequency
of this entity has declined because of the shift to breast con-
servation therapy for early stage mammary  carcinoma in the
last 20 years. AS originated in the breast can metastasize via
the blood system to the liver, lung, or bone. Both primary and
secondary breast angiosarcomas carry a prognosis worse than
mammary  carcinoma.
Primary AS of the breast typically occurs in younger women
without previous history of mammary  carcinoma or any asso-
ciated factor, a median age of onset between 20 and 40
years7 accounts for 0.04% of all malignant breast tumors.8 It
is usually present as rapidly growing palpable breast mass.
Disease free survival rates were reported between 18 and
36 months.9
Secondary angiosarcoma is usually found in older women
who  have undergone breast cancer treatment. The average
time between radiation therapy and AS development is 6
years, although several reports indicate this may occur as
early as 1–2 years or as late as 41 years after treatment.10
Postradiation AS was deﬁned by Cahan et al. and modiﬁed
by Arlen et al. as follows: location in the previous ﬁeld of
radiation, latency of years after radiation therapy, and histo-
logic distinction from the primary neoplasm.11,12 There are
two types: lymphedema-associated cutaneous and postradi-
ation angiosarcomas. Lymphedema-associated cutaneous AS
was ﬁrst described in 1948 by Stewart and Treves, also known
as Stewart–Treves syndrome, and it develops on the lym-
phedematous limb or chest wall after mastectomy and axillary
lymph node dissection. Increased use of breast conservation
therapy (BCT) and sentinel lymph node sampling has lowered
the incidence of treatment-related lymphedema.13
Postradiation angiosarcoma generally occurs after BCT
and RT and rarely arises in the irradiated chest wall afterrights reserved.
mastectomy. The ﬁrst case of secondary angiosarcoma in
the skin overlying an irradiated breast was reported in
1981.14 Since then, approximately 300 cases of post-radiation
angiosarcomas of the breast have been reported in English lit-
erature. In 2001, a retrospective study conducted by Huang
and Mackillop15 on 194,798 breast cancer patients treated
between 1973 and 1995, provided useful clues regarding this
relative risk. In this cohort of patients, the age standardized
incidence ratios for AS was 26.2 and 2.1 in the RT and non-
RT cohort, respectively. The study published in 2005 reported
that breast AS has a prevalence ranging between 0.002% and
0.005% per year.16 A recent study, however, suggests that
the incidence may be considerably higher (even more  than
0.3%).17
AS usually affects the dermis of the breast but occa-
sionally develops in the breast parenchyma. It can initially
resemble a bruise, or a raised purplish-red multifocal nod-
ules, eczematous rash, hematoma-like appearance or breast
swelling, which may delay the correct diagnosis.
The diagnostic of AS can be delayed due to unclear imag-
ing ﬁndings. In many  cases, radiographic assistance in making
the diagnosis is rather limited. Mammography may reveal
skin thickening and ill-deﬁned superﬁcial mass and therefore
these ﬁndings could be often non-speciﬁc. Sonographically,
angiosarcomas typically present as a hypervascular, het-
erogeneous and hyperechoic mass that is associated with
disruption of the normal breast architecture, so any dermal
lesions may be difﬁcult to differentiate from postradiation
skin thickening. MRI  seems to be the best option for deter-
mination of high-grade angiosarcomas. This is typically used
to ascertain lesion extension by showing a rapidly enhanc-
ing heterogeneous mass with hemorrhage or blood lakes. An
example of diagnostic challenges is a recent publication with
summary of imaging ﬁndings.18 The authors reported that
nearly 33% of patients with breast angiosarcomas had neg-
ative mammograms.
Early and low-grade AS may be subtle; differentiating low-
grade type from atypical postradiation vascular lesions may
be difﬁcult, because they both represent the low-grade end
of the morphologic spectrum of radiation-associated vascular
lesions. Classiﬁcation of vascular tumors according to WHO  is
described in Table 1. Since angiosarcomas are included within
the board category of vascular tumors (Table 1), differential
diagnosis is rather complicated and it requires expert histo-
logical assessment.19
From the histological point of view, the conﬁrmation of the
AS diagnosis is normally done by punch and core cut biopsy.
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Table 1 – Classiﬁcation of vascular tumors (WHO).
Reactive and benign
vascular tumors
Intermediate grade vascular
tumors
Malignant vascular
tumors
Tumors of perivascular
cells
Capillary haemangiomas Kaposi’s sarcoma Angiosarcoma Haemangiopericytoma
Cavernous haemangiomas Epithelioid haemangioendothelioma
Epithelioid haemangioma
Vascular ectasis
Angiomatosis
Postradiation atypical vascular
lesion
Table 2 – Overview of histologic grading of breast angiosarcoma adopted from Donnell et al.22
Histological ﬁndings Low grade Intermediate grade High grade
Lesion invading breast parenchyma Present Present Present
Hyperchromatic endothelial cells Present Present Present
Well-formed anastomosing Entirely Largely Scattered
Endothelial tufting Minimal Present Prominent
Papillary formations Absent Focally present Present
Solid and spindle cell foci Absent Absent or minimal Present
Mitoses Rare or absent Present in papillary area Numerous
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 low-grade AS exhibits an indolent, smoldering clinical
imilar to that of benign atypical vascular lesion. However,
ocal recurrences of low grade AS have been published.20,21
igh-grade AS is a very aggressive tumor which has a poorly
ifferentiated histology and, therefore, rather negative pro-
nostic indicator for patients. AS has a more  aggressive
ehavior than other histological types of cancer, while malig-
ant phyllodes tumors (i.e. those having >10 mitoses/10
igh power ﬁelds and marked stromal overgrowth) have
he metastatic rate of 20–30%. Often, high-grade AS may be
istaken for high-grade mammary  carcinoma. Nevertheless,
osen’s method for grading breast AS is easy to implement
nd correlates well with clinical outcome.22 Moreover, low
rade AS may transform into the high-grade type. The histo-
ogical grading of mammary  AS is shown in Table 2 and it is
mportant to emphasize that normally 60% of tumors have
igh histological grade with an inﬁltrative margin.23,24
AS typically express endothelial markers including von
illebrand factor, CD 34, CD 31, Ulex europaeus agglutinin 1,
nd vascular endothelial growth factor (VEGF). Immunohisto-
hemistry is therefore important in conﬁrming the diagnosis.
on Willebrand factor, U europaeus Agglutinin 1, and CD 31
re the most useful markers in poorly differentiated cases.25
n one study, more  than 89% of cells in two of the three postra-
iation angiosarcoma cases were CD117-positive (expression
f the tyrosine kinase receptor KIT).26 However, progres-
ive tumors dedifferentiation may lead to the loss of these
arkers. The absence of melanocytic markers (S100), human
elanoma black-45, and melanoma antigen can help distin-
uish angiosarcoma from melanoma.
.  Patients  and  methods retrospective analysis of the breast carcinoma and sar-
oma databases was done at St. Elisabeth Cancer Institute.
rom January 1995 to December 2011, approximately 4600Absent Present
Absent Present
patients were treated for breast tumors. Clinical and patholog-
ical factors such as age, mode of presentation, diagnostic and
treatment modalities, surgical pathology, loco-regional recur-
rence and survival rates were reviewed. Based on the database
records, only 3 patients were identiﬁed as having postradiation
AS of the breast. These cases were included and analyzed in
the framework of this study. All important details of patients
treated by the breast conservation therapy (BCT) for invasive
breast cancer (including diagnosis and treatment procedures
of secondary angiosarcoma) are shortly described in the fol-
lowing text.
Patient 1: A 44-year-old premenopausal woman was treated
for a T1N1M0 (stage IIA) invasive ductal carcinoma (grade 2,
l.sin (left side breast)) with quadrantectomy. The axillary dis-
section (in total 11 lymph nodes, one node was positive with
metastasis) and the surgery was performed on January 27,
1998. The size of the tumor was 20 mm and there was nega-
tive surgical margin. All investigated oncological markers were
negative (CEA, CA 15–3, TPS). The chemotherapy was admin-
istrated before (4× anthracycline) and after (2×  anthracycline)
radiotherapy. Postoperative adjuvant radiotherapy with TD
46.0 Gy (2 Gy per fraction, Co-60) followed by a 10.0 Gy electron
boost to the tumor bed was completed in July 1998. Thereafter,
Tamoxifen was prescribed (5 years). Only limited post radia-
tion dermatitis (stage I) was observed and there was no history
of breast or visible radiation effects.
The patient has no objective problems during a period of
12-years after BCT. She did well until next regular check-up
which took place in July 2010. There was no indication of
recurrence, although the patient reported local pain in the
area of treated breast. Standard diagnostic procedure by mam-
mography (MMG) and ultrasonography (USG) was completed
and there was no sign for loco-regional relapse. All investi-
gated oncological markers were also negative. However, two
weeks later, the patient claimed intensive pain in the left
axilla and arm. Although the pain was declining in this area
during next days, further complications occurred, speciﬁcally
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Fig. 1 – Patient 1 (a) mammography of the left breast – MLO  projection – increased density of ﬁbroglandular tissue with focal
appearance in the upper quadrant of the left breast, (b) MRI  of the breast-dynamic contrast enhanced study – markly
highenhanced inﬁltration with retractive changes and middle to 
an inﬂammation of mammilla and areola. She was treated
for suspect inﬂammation by standard antibiotics. The pain
occurred again and she ﬁrst noted a persistent “red-ring”
decoration of areola. A few days later, the patient reported fur-
ther induration of the central quadrant directly behind areola.
Based on anamnesis, there was a suspicion for mastitis (initial
phase). Further investigation by the percutaneous aspiration
biopsy (PAB) was done in July 2010. This result gave an indica-
tion for a local recurrence. Thereafter, local skin excision cutis
was completed in order to identify an origin of the indura-
tion, however, the ﬁnding was negative. Nevertheless, due to
observed ﬂat inﬁltration (34 mm × 22 mm),  a MRI was done on
August 16, 2010. The MRI  described some indication for a new
proliferated inﬁltration between the central and lower median
quadrant with further induration of the skin, deformation
of affected breast and retraction of its mammilla. Core-cut
biopsy performed after MRI  examination did not determine
any neoplastic changes, however, on the edge of the speci-
men  inﬂammatory mesenchymal cellulization was increased.
Recommended pathological conﬁrmation of the supraclavicu-
lar lymph node and PET examination were not performed,
because the patient decided to undergo antibiothical treat-
ment by her family doctor. This treatment was without
any therapeutical effect. Due to pending complications with
no improvement after conventional treatment, in January
2011, the patient came to the oncological centre for further
investigation. Immediately, mammography and ultrasound
examinations were performed. The outputs of these modal-
ities excluded inﬂammatory mastitis and indicated possible
tumorous changes of mastitis carcinomatosa. Very signiﬁcant
progress in the skin induration was conﬁrmed by MRI. Inﬁl-
trated region almost doubled its size (60 mm × 40 mm)  from
the previous control. Finally, high grade angiosarcoma was
conﬁrmed based on additional core-cut biopsy (Fig. 1).
Pathological ﬁndings conﬁrmed the inter-anastomosing
vascular channels which were intermingled with solid proliferating activity.
endothelial and spindle cell areas than showed necrotic
foci and numerous mitoses. Grade III (poorly differentiated)
angiosarcoma was diagnosed. In this particular case, more
than 50% of the total neoplastic area was composed of
solid and spindle cell components without evident vascu-
lar channels (Fig. 2). From January to March, the patient
received neoadjuvant chemotherapy (3 cycles of combination
Docetaxel 150 mg  and Gemcitabin 2000 mg). After chemother-
apy a simple left mastectomy was performed. Pathological
examination of a mastectomy specimen revealed satisfac-
tory post therapeutic response and only a minimal residual
angiosarcoma population was present. Regressive and repar-
ative changes were prevailing. Chemotherapy of further 3
cycles in the previous combination was applied. Chemother-
apy treatment was ended on June 22, 2011, 6 month after
beginning of the treatment. Further investigated control mam-
mography, ultrasound, MRI of the breast, CT of brain, chest
and abdomen were with negative results in terms of distant
metastases.
Patient 2: A 69-year-old women, had a T1N0M0 invasive duc-
tal carcinoma of the breast treated with lumpectomy. The size
of tumor was 10 mm.  The postoperative RT to 46.0 Gy (2 Gy per
fraction) was delivered. It was followed by a 10.0 Gy boost to
the tumor bed in July 2004. There was no history of breast or
arm edema or visible radiation late effect such as teleangiec-
tasia or ﬁbrosis. Similarly like case 1 and 2, this patient also
got hormonal therapy during 5 years period.
This patient had no signiﬁcant problems during follow-
ing 76 months, only sensitization of the treated breast, mild
pain and discreet lymphoedema was reported one year after
BCT. However, in November 2010, she had a sudden onset
of swelling over the breast with several “port wine” lesions
developed in the skin of the treated breast. During the next
week, the lesions appeared to decrease in size and fade, sug-
gesting resolution of a traumatic etiology to the following
clinician. Nine week later, however, there were well-deﬁned,
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Fig. 2 – Patient 1, core-cut biopsy (a) high-grade angiosarcoma, composed of neoplastic spindle cell population arranged in
cohesive clusters (distinct vascular spaces are formed and covered by hobnail cells), (b) hypercellular part of the
angiosarcoma, comprising of spindle and epitheloid cells with whorl formations and tiny capillaries, (c) breast amputation:
residual vascular spaces ﬁlled with erythrocytes and covered by atypical endothelial cells, placed in a hyaline stoma- this
represents the sole residual neoplastic formations of the previously diagnosed angiosarcoma (all pictures hematoxylin –
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 little purple–red, macular and papular skin lesions. USG
onﬁrmed hematoma-like appearance, with small petechial
esions. A biopsy specimen from April 24, 2011 was consis-
ent with atypical vascular proliferation, but suspicious for
ngiosarcoma (tumor size was 22 mm × 20 mm).  A total mas-
ectomy was completed on May 12, 2011 and it revealed
igh-grade AS extensively involving the skin, focally involv-
ng the breast parenchyma (Fig. 4). After surgery, the patient
eceived 8 cycles of adjuvant chemotherapy (paclitaxel 130 mg
eekly). Chemotherapy was ended three months later for
omplications which were neutropenia Gr.II leucopenia Gr.II
nd polyneuropathy.
Patient 3: A 70-year-old woman was treated for a left
reast T1N0M0 (AJCC stage I) invasive lobular carcinoma with
umpectomy. The size of the tumor was 17 mm with negative
urgical margins. The surgery was followed by postopera-
ive RT (46.0 Gy, 2 Gy per fraction) and a subsequent 10.0 Gy
lectron boost to the tumor bed. The treatment was com-
leted in October 1995. There was a history of discreet arm
dema one year after RT. Standard hormonal therapy was
ollowed (Tamoxifen for 5 years). Only limited post radiation
ermatitis (stage I) was observed. Comparably to case 1, there
as no evidence of other postradiation complications (edema,
eleangiectasia or ﬁbrosis).
The patient did well until December 2005 (10 years after
CT), when she ﬁrst noted a painful area and erythema of
he left arm and breast which occurred shortly after inﬂuenza
accination. She was treated for dermatitis with no improve-
ent. Six weeks later she noted a bruise on the breast and
he size of the lesion increased slightly, and small lumps were
oted under the scar. In January 2006, USG was done for diag-
osis of the root cause of pending problems. Due to unclearsonographic ﬁndings, a cytological examination by PAB was
done. This indicated possible local recurrence at the site of the
original breast tumor. Further investigation was done by MRI
which showed an intraparenchymal mass (75 mm × 25 mm).  A
biopsy specimen was taken and analyzed in February 2006 and
angiosarcoma was conﬁrmed. A total mastectomy on April 7,
2006 revealed high-grade angiosarcoma (grade 3, see Fig. 3)
involving only breast parenchyma without inﬁltration into the
skin and measuring 80 mm in diameter. Total mastectomy was
done with a negative margin (more than 20 mm).  Chemother-
apy was planned but not applied for cardiac contra-indication.
Subsequently, the patient was treated with external RT to
the chest wall with low-energy (6.0 MeV) electrons one frac-
tion daily to a total dose of 26.0 Gy (2 Gy per fraction). The
chemotherapy was not indicated and treatment was com-
pleted on June 9, 2006. As of July 31, 2012, the patient was
doing well, without evidence of recurrent disease after the
treatment.
3.  Results  and  discussion
Nowadays, breast conservation therapy with wide local exci-
sion and postoperative RT is the standard treatment of early
stage breast carcinomas. According to previously published
data, RT reduces local disease recurrence, but signiﬁcant side
effects exist from mild dermatitis to angiosarcoma.27,28 How-
ever, with the increasing diagnosis of early breast cancers,
amenable to breast conservation, an increase in the incidence
of secondary AS may be expected. The rarity of the dis-
ease and the unspeciﬁc clinical, histological and radiological
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Fig. 3 – Patient 2 (a) angiosarcoma of the breast: inﬁltration of the skin with high-grade spindle cell sarcoma with forming of
vascular spaces, prominent areas of hemorrhage and superﬁcial ulceration (hematoxylin – eosin stain, magniﬁcation 20×),
(b) invasion of the tumor to the deep adipose tissue of the breast (hematoxylin – eosin stain, magniﬁcation 100×), (c)
high-grade spindle cell sarcoma with slit-like spaces lined with atypical hobnail cells (hematoxylin – eosin stain,
magniﬁcation 200×).
features may signiﬁcantly delay its diagnosis. The treatment
approaches are brieﬂy discussed in the following paragraphs.
Generally, as regards the therapy, it is important to under-
line that AS treatment has to be planned by a multidisciplinary
team. Normally, surgery is the best way to achieve the local
control of this aggressive malignancy. However, currently
there are no standard guidelines concerning surgical margin.
Obtaining negative surgical margins is more  important than
the type of surgery.29,30 The standard surgical procedure is
Fig. 4 – Patient 3 (a) gross view of the breast angiosarcoma with 
detailed picture of the border between hypercellular spindle cell 
forming (hematoxylin – eosin stain, magniﬁcation 100×), (c) Imm
angiosarcoma of the breast (CD31 stain, magniﬁcation 20×).mastectomy with negative margins. It is recommended that
this should be carried out in a sarcoma specialist unit espe-
cially if the tumor is beyond the conﬁnes of the remaining
breast tissue or encroaching the chest wall. However, in case
of rapid growth after clinical manifestation, the tumor could
be inoperable. For locally advanced inoperable or metastatic
disease, chemotherapy is the pillar of treatment. Grade and
surgical margin status are important prognostic determinants
also in cases of post-irradiation sarcomas.31
cystic spaces and areas of heamorrhage on cut surface, (b)
component of the tumor and slit-like vascular spaces
unohistochemical stain of CD31 in high-grade
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Nowadays, the role of chemotherapy has not been fully
tandardized, as usually only short-lived responses are
eported in the literature. Treatment has been included in
anagement guidelines for other soft-tissue sarcomas, such
s those published by the European Society for Medical Oncol-
gy (ESMO) and the National Comprehensive Cancer Network
NCCN). Despite a strong need for systemic therapies, the
arity of angiosarcoma represents a major limitation to ran-
omized trials and therefore only few prospective clinical
tudies are available. Most data are represented by retro-
pective case series analyses or case reports, all suggesting
hat among soft tissue sarcomas, angiosarcoma appears to
e more  sensitive to cytotoxic chemotherapy.32 Angiosar-
omas are particularly sensitive to taxanes and liposomal
oxorubicin.33,34 This appears to be true also for breast AS
iven that some reports have conﬁrmed responses to these
gents.35 As a result, weekly paclitaxel or liposomal doxoru-
icin may be considered as valid alternatives to standard
nthracyclines plus/minus ifosfamide treatment for this par-
icular histology in view of their manageable adverse effect
roﬁle. In a phase II trial, paclitaxel has shown encourag-
ng results in unresectable angiosarcomas.36,37 Even if the
esponse rate of angiosarcoma to these treatments is high
ompared with other sarcomas, their dose-limiting toxic
ffects (mostly cardiac and neurological) do not allow to pro-
ong these therapies for >6–7 months in most cases.38 In
ddition, secondary resistance after response is frequent.
oreover, the combination of anthracyclines plus ifosfamide
an be difﬁcult to administer in many  angiosarcoma patients,
iven their age and PS. Postradiation secondary angiosar-
oma patients can be pretreated with anthracycline-based
hemotherapy, with a limited bone marrow reserve, and they
re likely to carry DNA repair mechanism defects that can
nderlie increased chemoresistance to cytotoxics like the
lkylating agent. In particular, the response rate to doxoru-
icin – the standard frontline chemotherapy for advanced
arcoma – as a single agent or in combination, is reported
o the range between 40% and 65%.39,40 Besides anthracy-
lines, taxanes can be active, both as single agents and in
ombination with gemcitabine or with anthracyclines, with
esponse rates between 20% and 65%.41,42. Responses to tax-
nes alone or in combination with gemcitabine are well
ocumented. In fact, tolerability of gemcitabine plus docetaxel
s fair, with less cardiac toxicity compared with anthracyclines
ut still carrying a signiﬁcant incidence of neutropenia and
hrombocytopenia.43,44 Only very few data are available on
emcitabine as a single agent. For these reasons, gemcitabine
eems to be a very promising therapeutic option.45,46 Among
ew angiogenesis-related molecules, the activity of sorafenib,
unitinib, bevacizumab, and thalidomide has been reported,
ith response rates of approximately 15%.47–49
Currently, most clinicians are reluctant to include radia-
ion treatment in the therapy plan because of surrounding
ealthy tissue radiation limits even years after initial RT.
he rationale underlying the use of hyperfractionated RT is
hat breast angiosarcomas have a high growth rate, making
hem more  likely to repopulate between daily fractions of
adiotherapy. The use of multiple daily fractions might, there-
ore, prevent repopulation from occurring. In 2002, promising
esults of neoadjuvant hyperfractionated RT in conjunctioniotherapy 1 9 ( 2 0 1 4 ) 37–46 43
with surgery for secondary AS were reported.50 The authors
reported 3 patients who were treated initially with radical
surgery for AS, but extensive recurrences were noted within
1 to 2 months after surgery. Because of the extremely rapid
growth noted before and after surgery, hyperfractionated RT
was used to a total dose of 60 Gy (1.5 Gy per fraction twice daily,
with a 6-hour interval between the daily fractions). The three
patients underwent planned resection after RT, and none of
the specimens demonstrated any evidence of AS. The patients
were alive without any recurrent disease 22–39 months after
treatment. Another, retrospective study of 13 patients, who
received hyperfractionated accelerated radiotherapy, showed
that this fractionation regimen is well tolerated and pro-
vides local control in nearly 60% of patients (three fractions
of 1 Gy per day, surgery before and after radiation). Their 5-
year overall survival was 86%.51 Hyperfractionated RT seems
effective for the treatment of postirradiation AS and warrants
further investigation. Although angiosarcoma is more  preva-
lent in cases treated with radiotherapy, occurring especially
in or adjacent to the radiation ﬁeld, this limited risk of subse-
quent secondary malignancies does not suppress the beneﬁt
of this modality. Due to the rarity of the condition, patients
are often present late in their path (course) of follow up and
disease progression is rapid. The median survival period is
14.5–34 months with a 5-year survival rate of approximately
15%.52
In our study, 3 cases of high-grade secondary angiosar-
coma of the breast were diagnosed and successfully treated
at St. Elizabeth Cancer Institute. The median age of pri-
mary breast cancer was 57 years (range 44–70 years). All
patients, after BCT, received external beam irradiation with
a median radiation dose of 50 Gy. Only limited post radi-
ation dermatitis (stage I) was observed and there was no
history of breast or arm edema or other visible radiation
effects such as teleangiectasis or ﬁbrosis. The median age
at diagnosis of secondary AS after BCT was 67 years (range
56–75 years), with a median latent period of 9 years (range
6–12 years). The presentation of AS was varied and included
purple cutaneous discoloration, eczematous rash, hematoma
like appearance, and breast swelling. There were no cases of
regional lymphadenopathy. Treated patients had preoperative
staging investigations before surgery. Tumor was extensively
involving the breast parenchyma (1 case) and skin and breast
parenchyma (2 cases) with varying degrees of nuclear atypia,
hyperchromatic nuclei, large nucleoli, and frequent mitoses,
“blood lakes” which represent hemorrhage into surrounding
stroma. Tumor grade is also known to be an important pro-
gnostic factor in cancer survival, however, it is perhaps not so
important in radiation induced angiosarcoma (RA), because
all our lesions are regarded as high grade. In our analysis, all
three patients underwent radical mastectomy with clear mar-
gins (more than 20 mm)  without axillary lymphadenectomy.
The ﬁrst patient was treated with neoadjuvant and adju-
vant chemotherapy (docetaxel and doxorubicin). The second
patient received chemotherapy with paclitaxel (neutrope-
nia grade II occurred). The third patient received adjuvant
radiotherapy (chemotherapy was not indicated due to car-
diotoxicity and age), and only radiodermatitis grade I was
presented after RT. Follow up evaluation after diagnosis of AS
ranged from 20 to 79 months, with a median of 22 months.
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Disease free period after treatment AS ranged from 9 to 73
months, with a median of 13 months. As of July 31, 2012,
our three patients were doing well, control mammography,
ultrasound, MRI  of the breast and brain, chest and abdomen
were with negative results in terms of distant metastases
after treatment. Although the follow up of our patients is
rather short, it is very important to report the clinical data
and experience in order to share best-practice which would
help obtain the earliest possible diagnosis of this rare but very
aggressive malignancy. The multimodal therapeutic approach
to this aggressive disease and comparison of clinical expe-
riences from other cancer institutes will be essential for
further improvement of early stage diagnostics and treatment
approaches.
In our study, the incidence of angiosarcoma was 0.065%
which corresponds to clinical data published recently. The
median age of diagnosis secondary AS after BCT was 75 years
(range 56–80 years), a latent period of 10 years (range 6–12
years) and the TNM classiﬁcation for primary breast carci-
noma was T1N0-1 (only one out of eleven nodes was detected
with micrometastasis in one case). Here comes the question
about radiotherapy outcome in the elderly presenting with
low-risk breast carcinoma? In a large-scale study of Radia-
tion Therapy Oncology Group (RTOG), and Eastern Cooperative
Oncology Group,53 636 women who were 70 years of age or
older and who  had clinical T1N0M0, stage I, according to
the tumor–node–metastasis classiﬁcation, estrogen receptor-
positive breast carcinoma were randomly assigned to receive
postoperatively tamoxifen plus radiation therapy or tamox-
ifen alone. The only signiﬁcant difference between the two
groups was found in the rate of LR or regional recurrence at
5 years (1% in the group given tamoxifen plus irradiation and
4% in patients given tamoxifen alone, P < 0.001). There were
no signiﬁcant differences between the two groups with regard
to 5-year rates of overall survival. The authors concluded
that lumpectomy plus adjuvant therapy with tamoxifen alone
is a realistic choice for the treatment of women aged 70
years or older who have early, estrogen receptor-positive
breast cancer. In summary, while the effectiveness of radia-
tion therapy in reducing LR after BCS in unselected patients
with early stage invasive breast cancer has been repeatedly
substantiated, the ratio between beneﬁts and risks of adju-
vant radiotherapy in highly selected, low-risk breast cancer
patients still remains to be explored prospectively at a large
scale.54
Finally, it is important to emphasize that much of the pub-
lished data on these rare tumors are based on case series,
which causes difﬁculty in interpretation of results, because
reporting may be selective, datasets incomplete, and treat-
ment approaches diverse, even within the same institution.
4.  Conclusions
Generally, the prognosis for angiosarcoma of the breast is
rather poor. Even though the association of the BCT and sec-
ondary AS is clear, it is frequently missed. The patients often
present late in their course of follow-up and disease progres-
sion is rapid. Diagnosis of AS can sometimes be troublesome,
the histological aspect may vary in the same tumor from thatdiotherapy 1 9 ( 2 0 1 4 ) 37–46
of a highly undifferentiated carcinoma to a form of benign vas-
cular hyperplasia. Therefore, the diagnosis may by incorrect,
particularly when only a small biopsy is taken (as in the case
presented here).
Breast conservation therapy with wide local excision and
postoperative RT is the standard treatment of early stage
breast carcinomas. According to previously published data, RT
reduces local disease recurrence, but signiﬁcant side effects
exist from mild dermatitis to angiosarcoma. However, with
the increasing diagnosis of early breast cancers, amenable
to breast conservation, an increase in the incidence of sec-
ondary AS may be expected. Angiosarcoma is more  prevalent
in cases treated with radiotherapy, occurring especially in or
adjacent to the radiation ﬁeld. With increasing use of breast
conservation therapy for breast cancer, number of reports on
postradiation angiosarcomas has increased. But the small dif-
ference in the risk of subsequent sarcoma for breast cancer
patients receiving radiotherapy does not supersede the beneﬁt
of radiotherapy.
In order to highlight this aggressive condition, rational
clinical aspects of presentation, treatment and outcomes
should be reported by clinicians as often as possible. Finally,
early stage diagnosis and appropriate combination of surgery,
chemotherapy and/or radiotherapy can improve a local con-
trol signiﬁcantly. In our study we presented and summarized
the clinical experience on combination of different modali-
ties done on individual basis in respect of speciﬁc patients’
conditions which brought successful results in the treatment
procedures.
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